Last reviewed · How we verify
Menadion (MENADIONE)
At a glance
| Generic name | MENADIONE |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | Vitamin D [EPC] |
| Target | Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- SIMPLAAFY Clinical Trial (NA)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- CHAMPION-AF Clinical Trial (NA)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menadion CI brief — competitive landscape report
- Menadion updates RSS · CI watch RSS
- Eli Lilly portfolio CI